Stock Market Reviews

ACRS (Aclaris Therapeutics, Inc.) News

Get the latest news, insights, and market updates on ACRS (Aclaris Therapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• With 56% institutional ownership, Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is a favorite amongst the big guns
  Key Insights Institutions' substantial holdings in Aclaris Therapeutics implies that they have significant influence...
  Sep 21, 2025 - $ACRS
• Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength?
  Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
  Sep 18, 2025 - $ACRS
• Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress
  - Late Breaking Abstract to Present Additional Data from Aclaris’ Phase 2a Trial of ATI-2138 in Atopic Dermatitis- WAYNE, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that a late-breaking abstract on its open-label Phase 2a trial of ATI-2138, a potent and selective investigational oral covalent inhibitor of interleukin-2
  Sep 9, 2025 - $ACRS
• This Aclaris Therapeutics Insider Increased Their Holding By 1,537% Last Year
  From what we can see, insiders were net buyers in Aclaris Therapeutics, Inc.'s ( NASDAQ:ACRS ) during the past 12...
  Aug 31, 2025 - $ACRS
• Aclaris Therapeutics to Participate in Two September Healthcare Conferences
  WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in September. On Wednesday September 3, 2025, at 1:00 PM EDT, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside cha
  Aug 27, 2025 - $ACRS
• Aclaris Therapeutics Reports Positive Phase 2a Clinical Trial Results for ATI-2138
  Aclaris Therapeutics Inc. (NASDAQ:ACRS) is one of the most promising penny stocks under $5. On July 29, Aclaris Therapeutics announced positive top-line results from its Phase 2a clinical trial of ATI-2138. This is a potent and selective oral inhibitor of interleukin-2-inducible T cell kinase/ITK and Janus kinase 3/JAK3, which are both enzymes involved in immune […]
  Aug 18, 2025 - $ACRS
• Earnings Beat: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
  It's been a good week for Aclaris Therapeutics, Inc. ( NASDAQ:ACRS ) shareholders, because the company has just...
  Aug 10, 2025 - $ACRS
• Aclaris: Q2 Earnings Snapshot
  WAYNE, Pa. AP) — Aclaris Therapeutics Inc. ACRS) on Thursday reported a loss of $15.4 million in its second quarter.
  Aug 7, 2025 - $ACRS
• Aclaris Therapeutics (ACRS) Reports Q2 Loss, Beats Revenue Estimates
  Aclaris (ACRS) delivered earnings and revenue surprises of 0.00% and +14.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 7, 2025 - $ACRS
• Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
  - Positive Clinical Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Confirm Tolerability Profile, Show Strong Efficacy Signal, and Validate ITK as Therapeutic Target - - Advanced Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) into Phase 2 Trial in Atopic Dermatitis (AD); Patient Dosing Underway - - Initiated Dosing in Phase 1a/1b Clinical Program for Anti-TSLP/IL-4R Bispecific Antibody ATI-052 - - Strong Cash Runway Expected to Fund Operations into the Second Half of 2028 - WAYNE,
  Aug 7, 2025 - $ACRS